Home » News » 01/06 » Roche to discontinue Konakion Neonatal

Roche to discontinue Konakion Neonatal

Date published: 17/01/2006

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that Roche is to discontinue Konakion Neonatal. Konakion Neonatal is primarily used to protect babies at birth with vitamin K deficiency and will be discontinued on March 31st this year.

The product will be replaced by Konakion MM Paediatric. The new treatment has previously been licensed to be given by injection or by mouth to premature babies and those at special risk. MHRA has also recently licensed it for intramuscular injection in healthy babies.

With the introduction of the new way to administer Konakion MM Paediatric health professionals are being advised that when given as an intramuscular injection the volume of the injection is different to that they are used to with the old product. MHRA has also licensed the use of Konakion MM Paediatric to reverse the effects of anticoagulant therapy in babies and infants, but under specialist advice.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.